Searches for User *djagoe* (Count = 15979)

Queries 15930 through 15979.

Find

Latest | Prev | Next | Oldest

Edit | Help | Return

S #	Updt	Database	Query	Time	Comment
S15979	U	PGPB,USPT,USOC,EPAB,JPAB,DWPI	6645972.pn.	2006-03-18 16:18:17	
S15978	U	PGPB,USPT,USOC,EPAB,JPAB,DWPI	(imatinib mesylate or gleevac or glivec or STE 571) and (suberoylanilide or vorinostat or SAHA!)	2006-03-18 15:00:42	
S15977	U	PGPB,USPT,USOC,EPAB,JPAB,DWPI	suberoylanilide or vorinostat or SAHA!	2006-03-18 15:00:27	
S15976	U	PGPB,USPT,USOC,EPAB,JPAB,DWPI	(Bcr$1Abl tyrosine kinase inhibitor) and (histone deacetylase inhibitor)	2006-03-18 14:59:30	
S15975	U	PGPB,USPT,USOC,EPAB,JPAB,DWPI	histone deacetylase inhibitor	2006-03-18 14:59:19	
S15974	U	PGPB,USPT,USOC,EPAB,JPAB,DWPI	Bcr$1Abl tyrosine kinase inhibitor	2006-03-18 14:58:43	
S15973	U	PGPB,USPT	Bcr$1Abl tyrosine kinase inhibitor	2006-03-18 14:58:30	
S15972	U	PGPB,USPT	(20030166557 and saha! or suberoylanilide) and (imatinib mesylate or gleevac or glivec or STE 571)	2006-03-18 14:52:57	
S15971	U	PGPB,USPT	imatinib mesylate or gleevac or glivec or STE 571	2006-03-18 14:52:43	
S15970	U	PGPB,USPT	(20030166557) and (saha! or	2006-03-18	

Show Saved Searches [redacted]

			suberoylanilide)	14:51:45
S15969	U	PGPB,USPT	(6645972.pn.) and (histone deacetylase inhibitor)	2006-03-18 14:43:51
S15968	U	PGPB,USPT	histone deacetylase inhibitor	2006-03-18 14:43:41
S15967	U	PGPB,USPT	(6645972.pn.) and (saha! or suberoylanilide)	2006-03-18 14:41:32
S15966	U	PGPB,USPT	saha! or suberoylanilide	2006-03-18 14:41:01
S15965	U	PGPB,USPT	20030166557	2006-03-18 14:18:29
S15964	U	PGPB,USPT	200300166557	2006-03-18 14:18:22
S15963	U	PGPB,USPT	(Minna.in.) and @pd=09042003	2006-03-18 14:17:59
S15962	U	PGPB,USPT	@pd=09042003	2006-03-18 14:17:46
S15961	U	PGPB,USPT	Minna.in.	2006-03-18 14:17:15
S15960	U	PGPB,USPT	2003/0166557	2006-03-18 14:16:49
S15959	U	PGPB,USPT	6645972.pn.	2006-03-18 14:16:28

Jagoe

=> d l1

L1 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2006 ACS on STN
RN 220127-57-1 REGISTRY
ED Entered STN: 03 Mar 1999
CN Benzamide, 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)
OTHER NAMES:
CN CGP 57148B
CN Gleevac
CN Gleevec
CN Glivec
CN Imatinib mesilate
CN **Imatinib mesylate**
CN STI-571
MF C29 H31 N7 O . C H4 O3 S
CI COM
SR CA
LC STN Files: ANABSTR, BIOSIS, BIOTECHNO, CA, CAPLUS, CHEMCATS, DDFU, DRUGU, EMBASE, HSDB*, IMSPATENTS, IMSRESEARCH, MRCK*, PATDPASPC, PROUSDDR, PS, RTECS*, SYNTHLINE, TOXCENTER, USPAT2, USPATFULL
(*File contains numerically searchable property data)

CM 1

CRN 152459-95-5
CMF C29 H31 N7 O



CM 2

CRN 75-75-2
CMF C H4 O3 S



Bcr-Abl TK. inhib.

A61K 31/19
514/575

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1195 REFERENCES IN FILE CA (1907 TO DATE)
15 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
1204 REFERENCES IN FILE CAPLUS (1907 TO DATE)

Jagoe

```
=> s suberoylanilide hydromaxic acid
             1 SUBEROYLANILIDE
             0 HYDROMAXIC
       7543010 ACID
L2           0 SUBEROYLANILIDE HYDROMAXIC ACID
                 (SUBEROYLANILIDE(W)HYDROMAXIC(W)ACID)

=> s suberoylanilide
L3           1 SUBEROYLANILIDE

=> d l3

L3   ANSWER 1 OF 1  REGISTRY  COPYRIGHT 2006 ACS on STN
RN   149647-78-9  REGISTRY
ED   Entered STN:  27 Aug 1993
CN   Octanediamide, N-hydroxy-N'-phenyl- (9CI)  (CA INDEX NAME)
OTHER NAMES:
CN   SAHA
CN   Suberoylanilide hydroxamic acid
CN   Vorinostat
FS   3D CONCORD
MF   C14 H20 N2 O3
SR   CA
LC   STN Files:   AGRICOLA, ANABSTR, BIOSIS, CA, CAPLUS, CASREACT, CIN,
       IMSRESEARCH, IPA, PHAR, PROMT, PROUSDDR, SYNTHLINE, TOXCENTER, USPAT2,
       USPATFULL
```



```
**PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT**

             218 REFERENCES IN FILE CA (1907 TO DATE)
               8 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
             222 REFERENCES IN FILE CAPLUS (1907 TO DATE)
```

Jagoe

L5 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 1
ACCESSION NUMBER: 2005:1313861 CAPLUS
DOCUMENT NUMBER: 144:45450
TITLE: Use of thioredoxin measurements for diagnostics and treatments
INVENTOR(S): Marks, Paul A.; Ungerstedt, Johanna
PATENT ASSIGNEE(S): Sloan-Kettering Institute for Cancer Research, USA
SOURCE: PCT Int. Appl., 81 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005117930	A2	20051215	WO 2005-US19523	20050603

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2004-577089P P 20040604

IT 302-79-4, Retinoic acid 146426-40-6, Flavopiridol 154361-50-9, Capecitabine **220127-57-1**, Imatinib mesylate
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(co-treatment with; use of thioredoxin expression measurements for diagnostics and monitoring treatments with histone deacetylase inhibitors and other therapeutic agents for hyperproliferative diseases)

IT 55-21-0D, Benzamide, derivs. 60-01-5, Tributyrin 79-09-4, Propanoic acid, biological studies 89-73-6, Salicylohydroxamic acid 99-66-1, Valproic acid 103-82-2, Phenylacetic acid, biological studies 109-52-4, Pentanoic acid, biological studies 156-54-7, Sodium butyrate 503-74-2 541-35-5, Butyramide 563-83-7, Isobutyramide 1821-12-1, Benzenebutanoic acid 16336-88-2, 3-Bromopropionate 18992-11-5, Azelaic bishydroxamic acid 30240-06-3, MW2996 53342-16-8, Chlamydocin 58880-19-6, Trichostatin A 68676-88-0, Trichostatin C 83209-65-8, HC-toxin 112522-64-2, CI-994 128517-07-7, FR901228 133155-89-2, Trapoxin A 136268-96-7, MW2796 139508-73-9, Depudecin **149647-78-9**, Suberoylanilide hydroxamic acid 149647-79-0 151720-43-3, Oxamflatin 174664-65-4, CBHA 174664-68-7 183506-66-3 191228-04-3, A-161906 209783-80-2, MS-27-275 209783-80-2D, MS-27-275, 3'-amino derivs. 258854-10-3, FR225497 287383-59-9, Scriptaid 382180-17-8, Pyroxamide 414864-00-9, PXD-101 442532-98-1, WF 27082 591207-53-3, LAQ 824 618056-29-4, CHAP
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of thioredoxin expression measurements for diagnostics and monitoring treatments with histone deacetylase inhibitors and other therapeutic agents for hyperproliferative diseases)

L5 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 2
ACCESSION NUMBER: 2005:1004984 CAPLUS
DOCUMENT NUMBER: 143:279368
TITLE: Pharmacodynamic assays for measuring blood cell response to MS-275 and other histone deacetylase inhibitors using flow cytometry in leukemia therapy
INVENTOR(S): Trepel, Jane; Chung, Eun Joo
PATENT ASSIGNEE(S): The Government of the United States of America, Asrepresented by the Secretary of the Department of Health and Human Services, USA
SOURCE: PCT Int. Appl., 58 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005085864	A1	20050915	WO 2005-US6236	20050225

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2004-548794P P 20040227
REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT
IT 60-01-5, Tributyrin 99-66-1, Valproic acid 103-82-2, Phenylacetic acid, biological studies 156-54-7, Sodium butyrate 1716-12-7, Sodium phenylbutyrate 16336-88-2, 3-Bromopropionate 58880-19-6, Trichostatin A 75747-14-7, 17-Allylaminogeldanamycin 112522-64-2, CI-994 128517-07-7, Fk228 133155-89-2 **149647-78-9**, Suberoylanilide hydroxamic acid 151720-43-3, Oxamflatin 174664-65-4 209783-80-2, MS-275 **220127-57-1**, Imatinib mesylate 382180-17-8, Pyroxamide 404951-53-7, NVP-LAQ824 414864-00-9, PXD101 618056-29-4, CHAP
RL: PAC (Pharmacological activity); BIOL (Biological study)
(pharmacodynamic assays for measuring blood cell response to MS-275 and other histone deacetylase inhibitors using flow cytometry in leukemia therapy)

L5 ANSWER 3 OF 16 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 3
ACCESSION NUMBER: 2005:99470 CAPLUS
DOCUMENT NUMBER: 142:197889
TITLE: Fluoro substituted omega-carboxyaryl diphenyl urea for treatment of raf, VEGFR, PDGFR, p38 and flt-3 kinase-mediated diseases
INVENTOR(S): Dumas, Jacques; Boyer, Stephen; Riedl, Bernd; Wilhelm, Scott
PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corporation, USA
SOURCE: PCT Int. Appl., 68 pp.
CODEN: PIXXD2

Jagoe

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005009961	A2	20050203	WO 2004-US23500	20040722
WO 2005009961	A3	20050331		
WO 2005009961	B1	20050602		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2005038080	A1	20050217	US 2004-895985	20040722
PRIORITY APPLN. INFO.:			US 2003-489102P P	20030723
			US 2004-540326P P	20040202

IT 50-07-7, Mitomycin C 50-18-0, Cyclophosphamide 50-24-8, Prednisolone 50-44-2, 6-Mercaptopurine 50-76-0, Dactinomycin 50-91-9, 5-Fluorodeoxyuridine 51-21-8, 5-Fluorouracil 52-24-4, Thiotepa 53-03-2, Prednisone 53-19-0, Mitotane 55-98-1, Busulfan 56-53-1, Diethylstilbestrol 57-22-7, Vincristine 57-85-2, Testosterone propionate 58-05-9, Leucovorin 58-96-8, Uridine 59-05-2, Methotrexate 71-58-9, Medroxyprogesterone acetate 76-43-7, Fluoxymesterone 125-84-8, Aminoglutethimide 127-07-1, Hydroxyurea 134-46-3, 5-Fluorodeoxyuridine monophosphate 147-94-4, Cytarabine 148-82-3, Melphalan 154-42-7, Thioguanine 154-93-8, Carmustine 305-03-3, Chlorambucil 320-67-2, 5-Azacytidine 446-86-6, Azathioprine 595-33-5, Megestrol acetate 630-56-8, Hydroxyprogesterone caproate 645-05-6, Hexamethylmelamine 671-16-9, Procarbazine 865-21-4, Vinblastine 3778-73-2, Ifosfamide 4291-63-8, Cladribine 4342-03-4, Dacarbazine 9015-68-3, Asparaginase 10540-29-1, Tamoxifen 11056-06-7, Bleomycin 13010-47-4, Lomustine 13311-84-7, Flutamide 13909-09-6, Semustine 15663-27-1, Cisplatin 18378-89-7, Plicamycin 18883-66-4, Streptozocin 19767-45-4, Mesna 20830-81-3, Daunorubicin 23214-92-8, Doxorubicin 25316-40-9, Adriamycin 29767-20-2, Teniposide 33069-62-4, Paclitaxel 33419-42-0, Etoposide 41575-94-4, Carboplatin 51321-79-0 53643-48-4, Vindesine 53910-25-1, Pentostatin 56420-45-2, Epirubicin 58957-92-9, Idarubicin 61825-94-3, Oxaliplatin 65271-80-9, Mitoxantrone 71486-22-1, Vinorelbine 75607-67-9, Fludarabine phosphate 84449-90-1 85622-93-1, Temozolomide 95058-81-4, 2',2'-Difluorodeoxycytidine 114977-28-5, Docetaxel 123948-87-8, Topotecan 128517-07-7, FR-901228 **149647-78-9**, Suberoylanilide hydroxamic acid 154361-50-9, Capecitabine 179324-69-7, Bortezomib 180288-69-1, Trastuzumab 183319-69-9, OSI-774 184475-35-2, ZD-1839 205923-56-4, Cetuximab 208921-02-2, Tositumomab 209783-80-2, MS-275 212141-54-3, PTK 787 216974-75-3, Bevacizumab **220127-57-1**, STI-571 257933-82-7, EKB-569 288383-20-0, AZD 2171 289499-45-2, CI-1033 380610-27-5, Pertuzumab 387867-13-2, MLN-518 437755-78-7, GW 2016 443913-73-3, ZD-6474 557795-19-4, SU 11248 591207-53-3, LAQ 824 777080-36-1, AG 13736 804551-71-1, CHIR 258

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination pharmaceutical; fluoro substituted omega-carboxyaryl di-Ph urea for treatment of raf, VEGFR, PDGFR, p38 and flt-3 kinase-mediated diseases)

L5 ANSWER 4 OF 16 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 4
ACCESSION NUMBER: 2005:1355554 CAPLUS
DOCUMENT NUMBER: 144:81158
TITLE: Use of thioredoxin measurements for diagnostics and treatments
INVENTOR(S): Marks, Paul A.; Ungerstedt, Johanna
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 39 pp., Cont.-in-part of U.S. Ser. No. 369,094.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 2005288227	A1	20051229	US 2005-144301		20050603
US 2003235588	A1	20031225	US 2003-369094		20030214
US 2006009526	A1	20060112	US 2005-223405		20050909
US 2006009527	A1	20060112	US 2005-223547		20050909
PRIORITY APPLN. INFO.:			US 2002-357383P	P	20020215
			US 2003-369094	A2	20030214
			US 2004-577089P	P	20040604

IT 302-79-4, Retinoic acid 146426-40-6, Flavopiridol 154361-50-9, Capecitabine **220127-57-1**, Imatinib mesylate
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(co-treatment with; use of thioredoxin expression measurements for diagnostics and monitoring treatments with histone deacetylase inhibitors and other therapeutic agents for hyperproliferative diseases)

IT 55-21-0D, Benzamide, derivs. 60-01-5, Tributyrin 79-09-4, Propanoic acid, biological studies 89-73-6, Salicylohydroxamic acid 99-66-1, Valproic acid 109-52-4, Pentanoic acid, biological studies 122-79-2, Phenyl acetate 156-54-7, Sodium butyrate 503-74-2 541-35-5, Butyramide 563-83-7, Isobutyramide 590-92-1, 3-Bromopropionic acid 1821-12-1, Benzenebutanoic acid 4346-18-3, Phenyl butyrate 18992-11-5, Azelaic bishydroxamic acid 30240-06-3, MW2996 53342-16-8, Chlamydocin 58880-19-6, Trichostatin A 68676-88-0, Trichostatin C 83209-65-8, HC-toxin 112522-64-2, CI-994 128517-07-7, FR901228 133155-89-2, Trapoxin A 136268-96-7, MW2796 139508-73-9, Depudecin **149647-78-9**, Suberoylanilide hydroxamic acid 149647-79-0 151720-43-3, Oxamflatin 174664-65-4, CBHA 174664-68-7 183506-66-3 191228-04-3, A-161906 209783-80-2, MS-27-275 209783-80-2D, MS-27-275, 3'-amino derivs. 258854-10-3, FR225497 287383-59-9, Scriptaid 382180-17-8, Pyroxamide 414864-00-9, PXD-101 442532-98-1, WF 27082 591207-53-3, LAQ 824 618056-29-4, CHAP
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of thioredoxin expression measurements for diagnostics and monitoring treatments with histone deacetylase inhibitors and other therapeutic agents for hyperproliferative diseases)

Jagoe

L5 ANSWER 5 OF 16 USPATFULL on STN
ACCESSION NUMBER: 2005:44347 USPATFULL
TITLE: Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
INVENTOR(S): Boyer, Stephen, Hilden, GERMANY, FEDERAL REPUBLIC OF
Dumas, Jacques, Bethany, CT, UNITED STATES
Riedl, Bernd, Wuppertal, GERMANY, FEDERAL REPUBLIC OF
Wilhelm, Scott, Orange, CT, UNITED STATES

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 2005038080	A1	20050217	
APPLICATION INFO.:	US 2004-895985	A1	20040722	(10)

	NUMBER	DATE	
PRIORITY INFORMATION:	US 2003-489102P	20030723	(60)
	US 2004-540326P	20040202	(60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: MILLEN, WHITE, ZELANO & BRANIGAN, P.C., 2200 CLARENDON BLVD., SUITE 1400, ARLINGTON, VA, 22201
NUMBER OF CLAIMS: 54
EXEMPLARY CLAIM: 1
LINE COUNT: 2492
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT 50-07-7, Mitomycin C 50-18-0, Cyclophosphamide 50-24-8, Prednisolone 50-44-2, 6-Mercaptopurine 50-76-0, Dactinomycin 50-91-9, 5-Fluorodeoxyuridine 51-21-8, 5-Fluorouracil 52-24-4, Thiotepa 53-03-2, Prednisone 53-19-0, Mitotane 55-98-1, Busulfan 56-53-1, Diethylstilbestrol 57-22-7, Vincristine 57-85-2, Testosterone propionate 58-05-9, Leucovorin 58-96-8, Uridine 59-05-2, Methotrexate 71-58-9, Medroxyprogesterone acetate 76-43-7, Fluoxymesterone 125-84-8, Aminoglutethimide 127-07-1, Hydroxyurea 134-46-3, 5-Fluorodeoxyuridine monophosphate 147-94-4, Cytarabine 148-82-3, Melphalan 154-42-7, Thioguanine 154-93-8, Carmustine 305-03-3, Chlorambucil 320-67-2, 5-Azacytidine 446-86-6, Azathioprine 595-33-5, Megestrol acetate 630-56-8, Hydroxyprogesterone caproate 645-05-6, Hexamethylmelamine 671-16-9, Procarbazine 865-21-4, Vinblastine 3778-73-2, Ifosfamide 4291-63-8, Cladribine 4342-03-4, Dacarbazine 9015-68-3, Asparaginase 10540-29-1, Tamoxifen 11056-06-7, Bleomycin 13010-47-4, Lomustine 13311-84-7, Flutamide 13909-09-6, Semustine 15663-27-1, Cisplatin 18378-89-7, Plicamycin 18883-66-4, Streptozocin 19767-45-4, Mesna 20830-81-3, Daunorubicin 23214-92-8, Doxorubicin 25316-40-9, Adriamycin 29767-20-2, Teniposide 33069-62-4, Paclitaxel 33419-42-0, Etoposide 41575-94-4, Carboplatin 51321-79-0 53643-48-4, Vindesine 53910-25-1, Pentostatin 56420-45-2, Epirubicin 58957-92-9, Idarubicin 61825-94-3, Oxaliplatin 65271-80-9, Mitoxantrone 71486-22-1, Vinorelbine 75607-67-9, Fludarabine phosphate 84449-90-1 85622-93-1, Temozolomide 95058-81-4, 2',2'-Difluorodeoxycytidine 114977-28-5, Docetaxel 123948-87-8, Topotecan 128517-07-7, FR-901228 **149647-78-9**, Suberoylanilide hydroxamic acid 154361-50-9, Capecitabine 179324-69-7, Bortezomib 180288-69-1, Trastuzumab 183319-69-9, OSI-774 184475-35-2, ZD-1839 205923-56-4, Cetuximab 208921-02-2, Tositumomab 209783-80-2, MS-275 212141-54-3, PTK 787 216974-75-3, Bevacizumab **220127-57-1**, STI-571 257933-82-7, EKB-569 288383-20-0, AZD 2171 289499-45-2, CI-1033 380610-27-5, Pertuzumab 387867-13-2, MLN-518 437755-78-7, GW 2016 443913-73-3, ZD-6474 557795-19-4, SU

11248 591207-53-3, LAQ 824 777080-36-1, AG 13736 804551-71-1, CHIR 258
(combination pharmaceutical; fluoro substituted omega-carboxyaryl di-Ph urea for treatment of raf, VEGFR, PDGFR, p38 and flt-3 kinase-mediated diseases)

L5 ANSWER 6 OF 16 SCISEARCH COPYRIGHT (c) 2006 The Thomson Corporation on STN
ACCESSION NUMBER: 2005:886301 SCISEARCH
THE GENUINE ARTICLE: 958IV
TITLE: Synergistic interactions between MEK1/2 and histone deacetylase inhibitors in BCR/ABL plus human leukemia cells
AUTHOR: Yu C; Dasmahapatra G; Dent P; Grant S (Reprint)
CORPORATE SOURCE: Virginia Commonwealth Univ, Med Coll Virginia, Div Hematol & Oncol, Massey Canc Ctr, Dept Med, MCV Stn Box 230, Richmond, VA 23298 USA (Reprint); Virginia Commonwealth Univ, Med Coll Virginia, Div Hematol & Oncol, Massey Canc Ctr, Dept Med, Richmond, VA 23298 USA; Virginia Commonwealth Univ, Massey Canc Ctr, Dept Biochem, Richmond, VA USA; Virginia Commonwealth Univ, Massey Canc Ctr, Dept Pharmacol, Richmond, VA USA
stgrant@hsc.vcu.edu
COUNTRY OF AUTHOR: USA
SOURCE: LEUKEMIA, (SEP 2005) Vol. 19, No. 9, pp. 1579-1589.
ISSN: 0887-6924.
PUBLISHER: NATURE PUBLISHING GROUP, MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND.
DOCUMENT TYPE: Article; Journal
LANGUAGE: English
REFERENCE COUNT: 46
ENTRY DATE: Entered STN: 8 Sep 2005
Last Updated on STN: 8 Sep 2005
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

AB . . . in K562 and LAMA 84 cells. Similar interactions were observed in CD34(+) cells from two patients with CML and in **imatinib mesylate**-resistant K562 cells but not in normal human CD34(+) bone marrow cells. These events were associated with a marked increase in. . .

STP KeyWords Plus (R): **SUBEROYLANILIDE** HYDROXAMIC ACID; CHRONIC MYELOID-LEUKEMIA; CHRONIC MYELOGENOUS LEUKEMIA; BCR-ABL ONCOGENE; KINASE INHIBITOR; TYROSINE KINASE; SELECTIVE INHIBITOR; OXIDATIVE STRESS; INDUCE APOPTOSIS; IMATINIB. . .

L5 ANSWER 7 OF 16 Elsevier BIOBASE COPYRIGHT 2006 Elsevier Science B.V. on STN DUPLICATE
ACCESSION NUMBER: 2005049216 ESBIOBASE
TITLE: New Drugs in Cancer Therapy, National Tumor Institute, Naples, 17-18 June 2004
AUTHOR: Caponigro F.; Basile M.; De Rosa V.; Normanno N.
CORPORATE SOURCE: F. Caponigro, National Tumor Institute, Fondazione 'G.Pascale', via M. Semmola, 80131 Naples, Italy.
E-mail: caponigrof@libero.it
SOURCE: Anti-Cancer Drugs, (2005), 16/2 (211-221), 61 reference(s)
CODEN: ANTDEV ISSN: 0959-4973
DOCUMENT TYPE: Journal; Conference Article
COUNTRY: United Kingdom
LANGUAGE: English

Jagoe

SUMMARY LANGUAGE: English

AB. . . in the research on anti-EGFR monoclonal antibodies may be represented by humanized monoclonal antibodies, such as EMD 72000 and ABX-EGF. **Imatinib mesylate** is probably the most outstanding example of an effective targeted therapy-its activity in gastrointestinal stromal tumors was so exciting that. . . for protein folding. Clinical data on depsipeptide, a histone deacetylase (HDAC) inhibitor with activity in T cell lymphoma, were presented. **Suberoylanilide** hydroxamic acid is another small molecular weight inhibitor of HDAC activity. Phase I/ II clinical trials have shown low toxicity. . .

L5 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 6

ACCESSION NUMBER: 2004:269998 CAPLUS
DOCUMENT NUMBER: 140:247047
TITLE: Method of treating leukemia with a combination of suberoylanilide hydroxamic acid and imatinib mesylate
INVENTOR(S): Bhalla, Kapil N.; Nimmanapalli, Ramedevi
PATENT ASSIGNEE(S): University of South Florida, USA
SOURCE: PCT Int. Appl., 12 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004026234	A2	20040401	WO 2003-US28964	20030919
WO 2004026234	A3	20040708		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2499189	AA	20040401	CA 2003-2499189	20030919
US 2004127571	A1	20040701	US 2003-605283	20030919
EP 1545536	A2	20050629	EP 2003-752375	20030919
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				

PRIORITY APPLN. INFO.:

US 2002-319563P	P	20020919
US 2003-605283	A	20030919
WO 2003-US28964	W	20030919

IT **149647-78-9**, Suberoylanilide hydroxamic acid **220127-57-1**, Imatinib mesylate
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(suberoylanilide hydroxamic acid-imatinib mesylate combination for leukemia treatment)

L5 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 7

ACCESSION NUMBER: 2004:252351 CAPLUS
DOCUMENT NUMBER: 140:264488
TITLE: Combination of a benzamide derivative and a histone

deacetylase inhibitor for the treatment of leukemia
INVENTOR(S): Dent, Paul; Grant, Steven; Krystal, Geoffrey; Yu, Chunrong
PATENT ASSIGNEE(S): Virginia Commonwealth University, USA; Mcguire Va Medical Center 111k
SOURCE: PCT Int. Appl., 37 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2004024160	A1	20040325	WO 2003-IB4053		20030910
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LT, LU, LV, MA, MD, MK, MN, MX, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SE, SG, SK, SY, TJ, TM, TN, TR, TT, UA, US, UZ, VC, VN, YU, ZA, ZW					
RW: AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR					
CA 2498210	AA	20040325	CA 2003-2498210		20030910
AU 2003259521	A1	20040430	AU 2003-259521		20030910
BR 2003014112	A	20050712	BR 2003-14112		20030910
EP 1553948	A1	20050720	EP 2003-795175		20030910
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
JP 2006501267	T2	20060112	JP 2004-535791		20030910

PRIORITY APPLN. INFO.:
US 2002-410286P P 20020913
US 2002-411344P P 20020918
WO 2003-IB4053 W 20030910

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

IT 156-54-7, Sodium butyrate 58880-19-6, Trichostatin A 128517-07-7, FK 228 **149647-78-9**, SAHA 152459-95-5 183506-66-3 209783-80-2, MS 275 **220127-57-1**, Glivec 404951-53-7 674775-92-9
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(combination of histone deacetylase inhibitor and antitumor benzamide derivative for treatment of leukemia)

L5 ANSWER 10 OF 16 CAPLUS COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:117798 CAPLUS
DOCUMENT NUMBER: 140:139491
TITLE: BCR-ABL tyrosine kinase and histone deacetylase inhibitors as antitumor agents for treatment of chronic myelocytic leukemia and PH-pos. acute lymphoid leukemia
INVENTOR(S): Karato, Masayuki
PATENT ASSIGNEE(S): Nagoya Industrial Science Research Institute, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 17 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2004043390	A2	20040212	JP 2002-204889	20020712
PRIORITY APPLN. INFO.:			JP 2002-204889	20020712

IT 99-66-1, Valproic acid 4346-18-3, Phenylbutyrate 58880-19-6, Trichostatin A 75621-03-3, CHAPs 128517-07-7, FR901228 **149647-78-9**, SAHA 209783-80-2, MS 27-275 **220127-57-1**, Imatinib mesylate
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(BCR-ABL tyrosine kinase and histone deacetylase inhibitors as antitumor agents for treatment of chronic myelocytic leukemia and PH-pos. acute lymphoid leukemia)

L5 ANSWER 11 OF 16 TOXCENTER COPYRIGHT 2006 ACS on STN
ACCESSION NUMBER: 2004:41454 TOXCENTER
COPYRIGHT: Copyright 2006 ACS
DOCUMENT NUMBER: CA14010139491P
TITLE: BCR-ABL tyrosine kinase and histone deacetylase inhibitors as antitumor agents for treatment of chronic myelocytic leukemia and PH-pos. acute lymphoid leukemia
AUTHOR(S): Karato, Masayuki
CORPORATE SOURCE: ASSIGNEE: Nagoya Industrial Science Research Institute
PATENT INFORMATION: JP 200443390 A2 12 Feb 2004
SOURCE: (2004) Jpn. Kokai Tokkyo Koho, 17 pp.
CODEN: JKXXAF.
COUNTRY: JAPAN
DOCUMENT TYPE: Patent
FILE SEGMENT: CAPLUS
OTHER SOURCE: CAPLUS 2004:117798
LANGUAGE: Japanese
ENTRY DATE: Entered STN: 20040224
Last Updated on STN: 20060221
RN 9076-57-7 (Histone deacetylase)
138238-67-2 (BCR-ABL tyrosine kinase)
99-66-1 (Valproic acid)
4346-18-3 (Phenylbutyrate)
58880-19-6 (Trichostatin A)
75621-03-3 (CHAPs)
128517-07-7 (FR901228)
149647-78-9 (SAHA)
209783-80-2 (MS 27-275)
220127-57-1 (Imatinib mesylate)

L5 ANSWER 12 OF 16 USPATFULL on STN
ACCESSION NUMBER: 2004:166081 USPATFULL
TITLE: Method of Treating Leukemia with a Combination of Suberoylanilide Hydromaxic Acid and Imatinib Mesylate
INVENTOR(S): Bhalla, Kapil N., 12902 Magnolia Drive, MRC-3E 3056D, Tampa, FL, UNITED STATES 33612
Nimmanapalli, Ramadevi, 12902 Magnolia Drive, MRC-3E 3056D, Tampa, FL, UNITED STATES 33612
PATENT ASSIGNEE(S): UNIVERSITY OF SOUTH FLORIDA, Tampa, FL, UNITED STATES (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004127571	A1	20040701

Jagoe

APPLICATION INFO.: US 2003-605283 A1 20030919 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-319563P	20020919 (60)

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: SMITH & HOPEN PA, 15950 BAY VISTA DRIVE, SUITE 220, CLEARWATER, FL, 33760
NUMBER OF CLAIMS: 16
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 3 Drawing Page(s)
LINE COUNT: 235
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
IT **149647-78-9**, Suberoylanilide hydroxamic acid **220127-57-1**
, Imatinib mesylate
(suberoylanilide hydroxamic acid-imatinib mesylate combination for leukemia treatment)

L5 ANSWER 13 OF 16 LIFESCI COPYRIGHT 2006 CSA on STN DUPLICATE 8
ACCESSION NUMBER: 2003:101336 LIFESCI
TITLE: An activated receptor tyrosine kinase, TEL/PDGF beta R, cooperates with AML1/ETO to induce acute myeloid leukemia in mice
AUTHOR: Grisolano, J.L.; O'Neal, J.; Cain, J.; Tomasson, M.H.
CORPORATE SOURCE: Departments of Medicine and Genetics, Division of Oncology, Washington University School of Medicine, Siteman Cancer Center, St. Louis, MO 63110; E-mail: Tomasson@im.wustl.edu
SOURCE: Proceedings of the National Academy of Sciences, USA [Proc. Natl. Acad. Sci. USA], (20030805) vol. 100, no. 16, pp. 9506-9511.
ISSN: 0027-8424.
DOCUMENT TYPE: Journal
FILE SEGMENT: G; B
LANGUAGE: English
SUMMARY LANGUAGE: English
AB . . . unique model of AML to test the efficacy of pharmacological inhibition of histone deacetylase activity by using trichostatin A and **suberoylanilide** hydroxamic acid alone or in combination with the tyrosine kinase inhibitor, **imatinib mesylate**. We found that although imatinib prolonged the survival of treated mice, histone deacetylase inhibitors provided no additional survival benefit. These. . .
UT. . . ETO gene; RUNX1 gene; CBF2T1 gene; trichostatin A; Gene fusion; Protein-tyrosine kinase receptors; AML1/ETO gene; platelet-derived growth factor receptors; mice; **suberoylanilide** hydroxamic acid; **imatinib mesylate**

L5 ANSWER 14 OF 16 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN DUPLICATE 9
ACCESSION NUMBER: 2003:569832 BIOSIS
DOCUMENT NUMBER: PREV200300562809
TITLE: The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571.
AUTHOR(S): Yu, Chunrong; Rahmani, Mohamed; Conrad, Daniel; Subler, Mark; Dent, Paul; Grant, Steven [Reprint Author]
CORPORATE SOURCE: Division of Hematology/Oncology, Medical College of

Jagoe

Virginia/Virginia Commonwealth University, MCV Station Box 230, Richmond, VA, 23298, USA
stgrant@hsc.vcu.edu
SOURCE: Blood, (November 15 2003) Vol. 102, No. 10, pp. 3765-3774. print.
CODEN: BLOOAW. ISSN: 0006-4971.
DOCUMENT TYPE: Article
LANGUAGE: English
ENTRY DATE: Entered STN: 3 Dec 2003
Last Updated on STN: 3 Dec 2003
RN . . . 80449-02-1 (Jun kinase)
155215-87-5 (EC 2.7.1.112)
80449-02-1 (EC 2.7.1.112)
616-91-1 (L-N-acetylcysteine)
179324-69-7 (bortezomib)
169592-56-7 (caspase-3)
179241-78-2 (caspase-8)
9076-57-7 (histone deacetylase)
220127-57-1 (imatinib mesylate)
152459-95-5 (imatinib mesylate)
220127-57-1 (STI571)
152459-95-5 (STI571)
165245-96-5 (p38 mitogen-activated protein kinase)
9026-43-1 (p38 mitogen-activated protein kinase)
165245-96-5 (EC 2.7.1.37)
9026-43-1 (EC 2.7.1.37)
9055-67-8 (poly(ADP-ribose)polymerase)
58319-92-9 (poly(ADP-ribose)polymerase)
9055-67-8 (EC 2.4.2.30)
58319-92-9 (EC 2.4.2.30)
7782-44-7 (reactive oxygen species)
156-54-7 (sodium butyrate)
149647-78-9 (suberoylanilide hydroxamic acid)

L5 ANSWER 15 OF 16 PASCAL COPYRIGHT 2006 INIST-CNRS. ALL RIGHTS RESERVED. on STN
ACCESSION NUMBER: 2003-0513684 PASCAL
COPYRIGHT NOTICE: Copyright .COPYRGT. 2003 INIST-CNRS. All rights reserved.
TITLE (IN ENGLISH): Cotreatment with the histone deacetylase inhibitor **suberoylanilide** hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells
AUTHOR: NIMMANAPALLI Ramadevi; FUINO Lianne; STOBAUGH Corinne; RICHON Victoria; BHALLA Kapil
CORPORATE SOURCE: Department of Interdisciplinary Oncology, Moffitt Cancer Center and Research Institute University of South Florida, Tampa, United States; Aton Pharma, Tarrytown, NY, United States
SOURCE: Blood, (2003), 101(8), 3236-3239, 24 refs.
ISSN: 0006-4971
DOCUMENT TYPE: Journal
BIBLIOGRAPHIC LEVEL: Analytic
COUNTRY: United States
LANGUAGE: English
AVAILABILITY: INIST-3178, 354000119367220470
TIEN Cotreatment with the histone deacetylase inhibitor **suberoylanilide** hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells

Jagoe

AB Here we demonstrate that treatment with SAHA (**suberoylanilide** hydroxamic acid), a known inhibitor of histone deacetylases (HDACs), alone induced p21 and/or p27 expressions but decreased the mRNA and. . .

CT. . . inhibitor; Biological activity; Antineoplastic agent; Drug combination; Apoptosis; Chromosome translocation; Abnormal chromosome C9; Abnormal chromosome G22; Philadelphia chromosome; Human; Blast; **Imatinib mesylate**

CTFR. . . biologique; Anticancereux; Association medicamenteuse; Apoptose; Translocation chromosomique; Chromosome C9 anormal; Chromosome G22 anormal; Chromosome Ph1; Homme; Histone deacetylase; Gene bcr; **Suberoylanilide** hydroxamic acid; Cellule blastique; Mesilate d'imatinib

L5 ANSWER 16 OF 16 BIOSIS COPYRIGHT (c) 2006 The Thomson Corporation on STN DUPLICATE 10

ACCESSION NUMBER: 2003:249361 BIOSIS
DOCUMENT NUMBER: PREV200300249361
TITLE: Histone deacetylase inhibitors promote STI571-mediated apoptosis in STI571-sensitive and -resistant Bcr/Abl+ human myeloid leukemia cells.
AUTHOR(S): Yu, Chunrong; Rahmani, Mohamed; Almenara, Jorge; Subler, Mark; Krystal, Geoffrey; Conrad, Daniel; Varticovski, Lubya; Dent, Paul; Grant, Steven [Reprint Author]
CORPORATE SOURCE: Division of Hematology/Oncology, Virginia Commonwealth University/Medical College of Virginia, MCV Station Box 230, Richmond, VA, 23298, USA
stgrant@hsc.vcu.edu
SOURCE: Cancer Research, (May 1 2003) Vol. 63, No. 9, pp. 2118-2126. print.
ISSN: 0008-5472 (ISSN print).
DOCUMENT TYPE: Article
LANGUAGE: English
ENTRY DATE: Entered STN: 28 May 2003
Last Updated on STN: 28 May 2003

RN 152459-95-5 (STI571)
142243-02-5 (extracellular signal-regulated kinase)
9076-57-7 (histone deacetylase)
220127-57-1 (imatinib mesylate)
142805-58-1 (mitogen activated protein kinase kinase)
9026-43-1 (mitogen activated protein kinase kinase)
142805-58-1 (EC 2.7.1.37)
9026-43-1 (EC 2.7.1.37)
149647-78-9 (suberoylanilide hydroxamic acid)
149647-78-9 (SAHA)

=> d his

(FILE 'HOME' ENTERED AT 14:27:05 ON 18 MAR 2006)

FILE 'REGISTRY' ENTERED AT 14:27:16 ON 18 MAR 2006
L1 1 S IMATINIB MESYLATE
L2 0 S SUBEROYLANILIDE HYDROMAXIC ACID
L3 1 S SUBEROYLANILIDE

FILE 'ADISCTI, ADISINSIGHT, ADISNEWS, BIOSIS, BIOTECHNO, CAPLUS, DDFB, DGENE, DISSABS, DRUGB, DRUGMONOG2, DRUGU, EMBAL, EMBASE, ESBIOBASE, IFIPAT, IMSDRUGNEWS, IMSPRODUCT, IPA, JICST-EPLUS, KOSMET, LIFESCI,

Jagoe

MEDLINE, NAPRALERT, NLDB, NUTRACEUT, PASCAL, ...' ENTERED AT 14:28:20 ON 18 MAR 2006

L4 36 S L1 AND L3

L5 16 DUP REM L4 (20 DUPLICATES REMOVED)